Navigation Links
Study Finds That Migraine Drug Can Ease The Severest Of Facial Pain

A new study in Japan has found migraine medication sumatriptan, known by the brand names Imitrex or Imigran, can provide relief for pain// due to trigeminal neuralgia up to eight hours.

Now researchers have found that a migraine medication could provide relief for people who suffer from, trigeminal neuralgia. Researchers had injected the drug and found it produced rapid and significant pain relief without serious adverse reactions.

Pain experienced with trigeminal neuralgia that affects the nerves in the face, sometimes known as tic douloureux, comes in lightning-like stabs that radiate from the angle of the jaw to the front of the face. The shocks are momentary but can repeat for several seconds. Paroxysms may last for hours, and then subside for long periods. This pain is often considered as one of the severest pains. Compression of the root of the trigeminal nerves by an artery is thought to cause trigeminal neuralgia.

Dr Akifumi Kanai and colleagues from Kitasato University School of Medicine explained this in the journal of Headache. The team led by Dr Kanai's examined the possible effectiveness of a subcutaneous injection of sumatriptan compared with saline in the treatment of trigeminal neuralgia in 24 patients. According to investigators, it was found to significantly decrease pain scores on a 0-10 scale from 8.3 to 2.4, according to the investigators. Pain scores did not change with placebo injection. Twenty patients described their pain as moderately or slightly better after sumatriptan treatment as compared with only one patient after being injected with saline injection. The analgesic effect of sumatriptan lasted for 1 to 20 hours, averaging 7.9 hours overall.

Dr Julio Pascual of University Hospital in Salamanca, Spain, in his editorial explained that the rapid onset of relief is plus, but subcutaneous injections that should be given at least twice a day would be a drawback. He went to suggest that sumatrip tan might be ideal as short-term treatment until oral drugs begin to work, or as rescue treatment. He also stated that he would like to see if other "triptans" that can be delivered orally or by nasal spray would work for trigeminal neuralgia.


'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for ... Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory ... disorder (ASD) to see films in an environment that accommodates their unique needs. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that ... of CM-AT in children aged 3-8 with Autism, is now enrolling at three new ... children across the United States. , “There are currently no approved drugs that ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017 Research and Markets has ... Strategies - 2016" report to their offering. ... The latest research Fibromyalgia Drugs ... benchmarks in the global Fibromyalgia market. The research answers ... drugs marketed for Fibromyalgia and their clinical attributes? How are they ...
(Date:2/23/2017)... , Feb 23, 2017 Research and ... Analysis & Trends - Industry Forecast to 2025" report to ... ... of around 6.9% over the next decade to reach approximately $47.6 ... market estimates and forecasts for all the given segments on global ...
(Date:2/23/2017)... 2017  MiMedx Group, Inc. (NASDAQ: MDXG), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic, and Dental sectors of healthcare, today announced its ... ended December 31, 2016. Full Year 2016 ... 31% increase over full year 2015 revenue ...
Breaking Medicine Technology: